ol-askofēns tabletes
olainfarm, as, latvija - skābes acetylsalicylicum, paracetamolum, kofeīns - tablete
hjertemagnyl 150 mg/21 mg apvalkotās tabletes
orifarm healthcare a/s, denmark - skābes acetylsalicylicum, magnija oxidum - apvalkotā tablete - 150 mg/21 mg
ubichinon compositum šķīdums injekcijām
biologische heilmittel heel gmbh, germany - ubidecarenonum, skābes ascorbicum, thiaminum hydrochloricum, nātrija riboflavinum phosphoricum, pyridoxinum hydrochloricum, nicotinamidum, rudens vēlziede (colchicum autumnale, podophyllum peltatum, conium plankumainas, hydrastis kanādas, skābes l-lacticum, hydrochinonum, skābes dl alfa-liponicum, sēru, manganum phosphoricum, nātrija diethyloxalaceticum, trichinoylum, naphthochinonum, para-benzochinonum, adenosinum triphosphoricum, coenzymum bija aparine, skābes acetylsalicylicum, histaminum, nadidum, magnija gluconicum, anthrachinonum, melleņu myrtillus - Šķīdums injekcijām
upsarin c 330 mg/200 mg putojošās tabletes
upsa sas, france - skābes acetylsalicylicum, skābes ascorbicum - putojošā tablete - 330 mg/200 mg
hjertemagnyl 75 mg/10,5 mg apvalkotās tabletes
orifarm healthcare a/s, denmark - skābes acetylsalicylicum, magnija oxidum - apvalkotā tablete - 75 mg/10,5 mg
duoplavin
sanofi winthrop industrie - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - antitrombotiskie līdzekļi - duoplavin ir indicēts aterotrombotiskām notikumiem pieaugušiem pacientiem, kas jau veic gan clopidogrel acetilsalicilskābes (asa) sekundārai profilaksei. duoplavin is a fixed-dose combination medicinal product for continuation of therapy in:non st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention (pci);st segment elevation acute myocardial infarction (stemi) in patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. sīkāku informāciju, lūdzu, skatiet sadaļā 5.
upsarin c 330 mg/200 mg putojošās tabletes
upsa sas, france - skābes acetylsalicylicum, skābes ascorbicum - putojošā tablete - 330 mg/200 mg
upsarin c 330 mg/200 mg putojošās tabletes
upsa sas, france - skābes acetylsalicylicum, skābes ascorbicum - putojošā tablete - 330 mg/200 mg
upsarin c 330 mg/200 mg putojošās tabletes
upsa sas, france - skābes acetylsalicylicum, skābes ascorbicum - putojošā tablete - 330 mg/200 mg
rapilysin
actavis group ptc ehf - reteplase - miokarda infarkts - antitrombotiskie līdzekļi - rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent st elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (ami) symptoms.